DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?

The clinical impact of non-alcoholic fatty liver disease (NAFLD) is not confined to liver-related morbidity and mortality, but also extends to serious adverse extra-hepatic outcomes, increasing the risk of chronic kidney disease and cardiovascular disease [1]. Over the last decades, it has been shown that these risks are higher in patients with fatty liver disease associated with metabolic dysfunction [2]. For this reason, the term “metabolic (dys-function) associated fatty liver disease (MAFLD)” has recently been proposed as a replacement for the term “NAFLD” [3]. The definition of MAFLD emphasizes the importance of over-weight/obesity, type 2 diabetes mellitus, insulin resistance, and other metabolic risk abnormalities that fuel the risk of liver disease progression and the development of serious adverse extra-hepatic outcomes [2,3]. Advanced liver fibrosis is more common in patients with type 2 diabetes mellitus (T2DM)